Unpacking IO Innovations in Lung Cancer in Pittsburgh

We recently traveled to Pittsburgh, Pennsylvania, for a State of the Science Summit on Lung Cancer. At the meeting, faculty from the University of Pittsburgh Medical Center and Fox Chase Cancer Center discussed how chemoimmunotherapy has changed the standard of care in stage IV nonsquamous NSCLC, highlighted how up-front immunotherapy has become a pivotal part of treatment in squamous NSCLC, and explained how immunotherapy’s success in lung cancer has set the stage for future research. In addition, faculty examined PD-L1 and tumor mutational burden as biomarkers of immunotherapy response in NSCLC, and provided insight into overcoming acquired resistance to targeted therapy.